IGM BIOSCIENCES, INC.
IGMS US4495851085
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -62% | -43% | -51% | -30% | 6% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Harler Mary Beth CEO |
1.27 USD |
14,501 Sold |
18,457 USD |
23/07/2025 | 23/07/2025 |
| Decker Lisa Lynn SR OFF |
1.27 USD |
4,409 Sold |
5,612 USD |
23/07/2025 | 23/07/2025 |
| Harler Mary Beth CEO |
1.27 USD |
14,501 Sold |
18,457 USD |
23/07/2025 | 23/07/2025 |
| Tahir Misbah CFO |
1.27 USD |
8,741 Sold |
11,126 USD |
23/07/2025 | 23/07/2025 |
| Harler Mary Beth CEO |
1.20 USD |
1,522 Sold |
1,825 USD |
16/06/2025 | 16/06/2025 |
| Weber Steven CCO |
1.20 USD |
486 Sold |
583 USD |
16/06/2025 | 16/06/2025 |
| Harler Mary Beth CEO |
1.20 USD |
1,522 Sold |
1,825 USD |
16/06/2025 | 16/06/2025 |
| Weber Steven CCO |
1.20 USD |
486 Sold |
583 USD |
16/06/2025 | 16/06/2025 |
| Tahir Misbah CFO |
1.20 USD |
1,522 Sold |
1,825 USD |
16/06/2025 | 16/06/2025 |
| Tahir Misbah CFO |
1.20 USD |
1,522 Sold |
1,825 USD |
16/06/2025 | 16/06/2025 |